Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline
10:33am, Wednesday, 30'th Oct 2019
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Reata Is A 'Show Me' Story Showing The Results And With 2 Upcoming Catalysts
06:20am, Monday, 21'st Oct 2019
Strong omaveloxolone results in FA was a surprise and could generate $1B+ in sales. Importantly, their Nrf2 activators could potentially treat many other neurodegenerative indications beyond FA.
Reata CEO on positive trial results for drug to treat Friedreich's ataxia
06:59pm, Friday, 18'th Oct 2019
Warren Huff, Reata Pharma CEO, joins CNBC's "Power Lunch" team to discuss his company's positive clinical trial results for a drug to treat the neuromuscular disease Friedreich's ataxia.
3 Companies to Watch At Kidney Week 2019
05:36pm, Friday, 18'th Oct 2019
Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
Reata (RETA) Jumps: Stock Rises 5. 6%
08:58am, Thursday, 17'th Oct 2019
Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Reata Pharmaceuticals Repositions Itself for Success
04:14pm, Wednesday, 16'th Oct 2019
The company reclaimed rights to several promising drug candidates last week; this week, positive data from a pivotal clinical trial sent it soaring.
Reata Successfully Completes Neuromuscular Disorder Study
05:13pm, Tuesday, 15'th Oct 2019
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
Why Aphria, Reata Pharmaceuticals, and NVIDIA Jumped Today
04:28pm, Tuesday, 15'th Oct 2019
Earnings results and favorable comments lifted several stocks.
Reata soars on positive drug trial results
03:08pm, Tuesday, 15'th Oct 2019
CNBC's Meg Tirrell reports on positive drug trial results from Reata Pharmaceuticals that sent shares higher.
Here's Why Reata Pharmaceuticals Skyrocketed Higher Today
01:37pm, Tuesday, 15'th Oct 2019
Data from a phase 2 study looks promising.
Why This Neuromuscular Disorder Study Could Be the Next Big Thing
12:35pm, Tuesday, 15'th Oct 2019
Reata Pharmaceuticals Inc. (NASDAQ: RETA) shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial.
Biotech Stock Rockets 34% After Decision To Reacquire Its Drugs Pays Off
06:36pm, Monday, 14'th Oct 2019
Reata Pharmaceuticals soared late Monday on positive results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.
Reata neuromuscular disorder drug meets study endpoint, stock halted
04:16pm, Monday, 14'th Oct 2019
Reata Pharmaceuticals Inc. RETA, +4.99% shares were halted after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment.
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT
Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019
10:00am, Friday, 11'th Oct 2019
IRVING, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical an
